

Case Study | Dipharma

Understanding when a drug can become generic

API manufacturer Dipharma did not have the reliable data it needed to make accurate decisions, so it turned to Cortellis Generics Intelligence™ because of its reliable and independently validated product and patent intelligence.

Cortellis Generics Intelligence has contributed to the growth of Dipharma's business by:



reducing the workload for generic portfolio selection,



gaining insight as to when drugs can go generic,



helping the organization monitor competition and



saving four to five hours per week due to increased productivity.

"[Cortellis Generics Intelligence] is one of the key starting points for identifying new potential generics and is our first choice to collect all relevant information about said generics to get a full picture of the value of the compound for the company."

Florian Thaler, Head of Patents, Dipharma

For more information on how Cortellis Generics intelligence can help you grow your business and stay ahead of the competition visit our website at:

clarivate.com/genericsintelligence

© 2020 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

This case study is based on a February 2020 survey of Newport (now know as Cortellis Generics Intelligence) customers by a third-party research service.